135,100 Shares in Soleno Therapeutics, Inc. $SLNO Acquired by Eagle Health Investments LP

Eagle Health Investments LP acquired a new position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 135,100 shares of the company’s stock, valued at approximately $6,255,000. Soleno Therapeutics accounts for about 1.4% of Eagle Health Investments LP’s portfolio, making the stock its 20th biggest position. Eagle Health Investments LP owned about 0.25% of Soleno Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Raymond James Financial Inc. acquired a new position in shares of Soleno Therapeutics in the second quarter worth approximately $25,000. Danske Bank A S acquired a new position in shares of Soleno Therapeutics in the third quarter worth approximately $27,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Soleno Therapeutics in the third quarter worth approximately $37,000. Quarry LP acquired a new position in shares of Soleno Therapeutics in the third quarter worth approximately $47,000. Finally, Quantbot Technologies LP acquired a new position in shares of Soleno Therapeutics in the third quarter worth approximately $67,000. 97.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SLNO. Wells Fargo & Company set a $53.00 price objective on Soleno Therapeutics and gave the stock an “equal weight” rating in a research note on Friday, April 17th. Zacks Research downgraded Soleno Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Cantor Fitzgerald reiterated a “neutral” rating on shares of Soleno Therapeutics in a report on Tuesday. Finally, Lifesci Capital downgraded Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Three investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $76.67.

Soleno Therapeutics Stock Performance

Shares of SLNO stock opened at $53.01 on Thursday. The company has a market cap of $2.76 billion, a P/E ratio of 29.95 and a beta of -2.22. The stock has a 50 day simple moving average of $45.79 and a two-hundred day simple moving average of $45.46. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.32 and a current ratio of 5.62. Soleno Therapeutics, Inc. has a fifty-two week low of $29.43 and a fifty-two week high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. Soleno Therapeutics had a return on equity of 22.85% and a net margin of 33.70%. Research analysts forecast that Soleno Therapeutics, Inc. will post 3.67 earnings per share for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.